Testimonials
Customers Testimonials – LRC-TriCEPS Service
Please see below the testimonials from our customers who have used the LRC-TriCEPSTM technology – CaptiRec – in collaboration with Dualsystems Biotech AG.
La BioMed
PUBLICATION: Li Z, Zeppa JJ, Hancock MA, McCormick JK, Doherty TM, Hendy GN, and Madrenas J. Staphylococcal Superantigens Use LAMA2 as a Coreceptor To Activate T Cells. J Immunol. 2018; 200: 1471-1479.
The identification of a T cell co-receptor for staphylococcal superantigens had been challenging due to the structural features of the interaction and its kinetics. However, working with Dualstystems Biotech AG, and with Dr. Paul Helbling in particular, and using the LRC-TriCEPS technology, we were able to identify a candidate that was subsequently corroborated by biochemical and functional assays. We are very happy with this collaboration , and sincerely recommend it for the identification of novel receptor or co-receptor candidates.
(Quim) Madrenas, MD, PhD, FCAHS
Chief Scientific Officer
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance,USA
Follicum
Important new receptors for Follicum’s lead candidate FOL-005 in hair follicle cells identified.
Igenica Biotherapeutics
“Leveraging Dualsystems Biotech novel linker technology (LRC-TriCEPS) and its analytical data processing capabilities we were able to identify the heterophilic receptor for a highly-pursued immuno-oncology target.“
Update 2017: Pierre Fabre Pharmaceuticals acquires promising assets from Igenica Biotherapeutics in the field of immuno-oncology (PDF)
Dr. Edward van der Horst,
Senior Director, Preclinical Development
Igenica Biotherapeutics
QIMR Berghofer Medical Research Institute, Australien
“With the help of the team at Dualsystems we confirmed a potential receptor which has lead to a Nature paper submission and successful funding of a research grant. The LRC-TriCEPS experiment was straightforward and the process was cost effective. We look forward to using TriCEPS in the future.”
Anita Burgess | PhD
Hepatic Fibrosis Group
QIMR Berghofer Medical Research Institute, Australia
University of Miami, Miller School of Medicine
We are very pleased with the experience and interaction on very high professional level with Dualsystems Biotech. As a result of such collaboration the new receptor MUC5B was identified in human chondrosarcoma cells for the first time for antiproliferative neuropeptide PRP-1. This led to publication of the major manuscript and, most importantly, it opens up many interesting clinical and basic science possibilities for further exploration of this peptides mode of action. I would recommend this reputable company to any researcher interested in the search for new receptor candidates. The Triceps technology is so innovative in its design, which captures receptor candidates thus eliminating, months and months of otherwise extra tedious receptor search procedures.
I would like to thank once again the company and, particularly, Dr Helbling for his attention and collaboration.
Dr Karina Galoian
Research associate professor
University of Miami, Miller School of Medicine
Department of Orthopedic surgery
Miami, Florida, USA
Münster University Hospital (UKM)
“Dualsystems Biotech’s approach to receptor identification with the TriCEPS reagent gave us a powerful platform with great support for a successful and fast data generation, when conventional approaches had previously failed.”
Dr. rer. nat. Martin Herold
Working group from Prof. Dr. med. Luisa Klotz
Münster University Hospital (UKM), Germany
University of Manitoba
“Every aspect of our experience with Dualsystems Biotech was outstanding. They provided excellent customer service and technical support throughout the entire process. Their LRC-TriCEPS technology allowed us to identify several new candidate receptors for our protein of interest in rat primary neurons, and this has created new and exciting avenues for our research.”
Sari S. Hannila, PhD, Associate Professor, Department of Human Anatomy and Cell Science
Associate Member, Spinal Cord Research Centre, Max Rady College of Medicine, Rady Faculty of Health Sciences
University of Manitoba
The Rockefeller University
“We are very pleased with the work product of Dualsystems Biotech. The TriCEPS reagent allowed us to identify a novel ligand-extracellular matrix protein receptor interaction, which was not possible using traditional techniques. The Dualsystems team were very helpful in tailoring the experimental conditions to fit our biological question.”
Manish Ponda, M.D., M.S., Assistant Professor of Clinical Investigation
The Rockefeller University
Medizinische Hochschule Hannover
“With the support of Dualsystems Biotech and their LRC-TriCEPS technology we were able to identify receptor candidates for our peptide with renoprotective properties in kidney injury.“
Dr. rer. nat. Inga Sörensen-Zender, Postdoc
Medizinische Hochschule Hannover
East Tennessee State University
“For the ligand sample two unique receptors were identified. Flow cytometry analysis with siRNA induced knockdown of these proteins confirmed that the presence of the protein is needed for CTRP3 binding to occur. CONCLUSION The LRC-TriCEPS methodology was successful in identifying the receptor for CTRP3.”
Jonathan M Peterson
Assistant Professor
East Tennessee State University
CEDOC – Centro de Estudos de Doenças Crónicas
New publication October 2015 in Nature Communications using the LRC-TriCEPS technology in collaboration with Alisson M. Gontijo, Principal Investigator at CEDOC (Centro de Estudos de Doenças Crónicas)
« The fruitful collaboration with Dualsystems Biotech using the LRC-TriCEPS (CaptiRec) technology showed that even on insect cells receptors could be identified »
Alisson M. Gontijo,
Principal Investigator at CEDOC
Centro de Estudos de Doenças Crónicas
University of California San Francisco (UCSF)
“We have been trying to identify a receptor that has been sought after for nearly 30 years by laboratories across the globe. Thanks to Dualsystems service CaptiRec (LRC-TriCEPS), we now have a strong candidate receptor.”
De’Broski R. Herbert Ph.D.
Assistant Professor in Residence
University of California San Francisco (UCSF)
Washington University School of Medicine
“Thanks to LRC-TriCEPS (CaptiRec) technology we were able to identify a long sought receptor of our ligand using genetically-engineered cell lines with the support of Dualsystems”
Fumihiko Urano, MD, PhD
Samuel E. Schechter Professor of Medicine
Washington University School of Medicine
